Pearce IP BioBlast: w/e 07 August 2020

Significant biosimilar activities this week include:

  • 31 Jul 20, US: Vizient has advised its member health groups to utilise biosimilars to hedge against drug price inflation and the impacts of COVID-19.  Vizient predicts that drug prices in the US will increase by 3.29% in 2021.
     

  • 03 Aug 20: Celltrion has gained WHO prequalification for its trastuzumab biosimilar Herzuma®.  The prequalification status enables Celltrion to make a bid in global procurement by UN agencies, and is based on an evaluation of safety and efficacy.
     

  • 05 Aug 20: Alvotech and Teva announced a strategic partnership to collaborate on five biosimilar product candidates in the US market.  Under the agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, while Teva will be exclusively commercialising the products in the US.  The agreement includes an upfront payment, with subsequent milestone payments, with Alvotech and Teva to share the profits from commercialisation.
     

  • 06 Aug 20, IN: Cadila Pharmaceuticals launched NuPTH® (biosimilar teriparatide) in India.  NuPTH® is indicated for osteoporosis and in patients with increased risk of fracture. 
     

  • 07 Aug 20: OncLive published an interview with Manfred Welslau, MD on the findings from the interim results of Sandoz's REFLECT study of SDX-RTX (rituximab biosimilar).   These results reconfirmed the safety and efficacy profile of the product, which has already been approved in the EU, Switzerland, Japan, New Zealand and Australia.  Welslau announced that the full results of this study will be released at the end of 2020 or the beginning of 2021.  

Share on Facebook
Share on Twitter
Please reload

Biosimilars Bulletin 

August 19, 2020

Please reload

Search by tags